- OpGen ( NASDAQ: OPGN ) announced Friday the preliminary second quarter estimates with revenue expected to be $1M, up from $0.8M in prior year.
- "We are excited by the progress made in the second quarter, especially the fact that in June we signed the first commercial contract for our Acuitas AMR Gene Panel in the U.S. with a major hospital in the Northeast, the expansion of our distribution partnership with Menarini with significantly increased annual minimum revenue commitments by Menarini along with the agreement whereby Menarini has purchased the entire European pool of Unyvero systems across 9 countries from us at residual fair market value," stated President and CEO Oliver Schacht.
- Cash as of June 30, 2022 was approximately $16.6M.
For further details see:
OpGen reports preliminary revenue estimate for Q2 2022